EnClear Therapies
Manuel N. has extensive work experience in the field of drug discovery and development. Manuel began their career in 1993 as the founder of Altus Pharmaceuticals, where they also served on the Board of Directors and Scientific Advisory Board until 2010. In 2003, Manuel became the President of Hub-Bio Strategic Advising, providing strategic advice in drug discovery and development. From 2003 to 2016, they also worked as an Executive-in-Residence at Oxford Bioscience Partners.
In the years following, Manuel co-founded several companies, including Estabrook Pharmaceuticals in 2008, eXIthera Pharmaceuticals in 2012, and EnClear Therapies in 2018. Manuel also served as a Drug Discovery and Development Advisor at QurAlis, Artugen Therapeutics, ClearB Therapeutics, Stealth BioTherapeutics, and eXIthera Pharmaceuticals, contributing their expertise in the field. Overall, Manuel N. has consistently demonstrated their knowledge and skills in drug discovery and development throughout their diverse work experience.
Manuel N. began their education in 1964 at New York University, where they pursued a Bachelor of Arts (BA) degree in Physics. Manuel completed their undergraduate studies in 1967. Subsequently, from 1967 to 1969, they attended the University of Chicago to obtain a Master of Science (MS) degree in Biophysics. Continuing their academic journey, Manuel pursued a Doctor of Philosophy (PhD) degree in Biophysics at the University of Chicago from 1972 to 1974.
This person is not in any teams
EnClear Therapies
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).